Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.48 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6307483 | 1.00 | POLB (0.60) | POLBL3MBTL1ALDH1A1GAAKMT2A | |
| SCHEMBL3505013 | 0.87 | MAOB (0.47) | POLBL3MBTL1ALDH1A1KMT2AMEN1 | |
| SCHEMBL3505017 | 0.87 | MAOB (0.47) | POLBL3MBTL1ALDH1A1KMT2AMEN1 | |
| SCHEMBL4467004 | 0.87 | POLB (0.76) | POLBL3MBTL1ALDH1A1GAAKMT2A | |
| SCHEMBL13919525 | 0.87 | POLB (0.76) | POLBL3MBTL1ALDH1A1GAAKMT2A | |
| SCHEMBL6309095 | 0.86 | MAOB (0.46) | L3MBTL1KMT2AMEN1NR4A2MAOB | |
| SCHEMBL5823994 | 0.86 | MAOB (0.46) | POLBL3MBTL1ALDH1A1KMT2AMEN1 | |
| SCHEMBL5618422 | 0.86 | MAOB (0.46) | POLBL3MBTL1ALDH1A1KMT2AMEN1 | |
| SCHEMBL6309098 | 0.86 | MAOB (0.46) | L3MBTL1KMT2AMEN1NR4A2MAOB | |
| SCHEMBL6309099 | 0.86 | MAOB (0.46) | L3MBTL1KMT2AMEN1NR4A2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1277820-C | Phthalimido derivatives as inhibitors of monoamine oxidase B | HOFFMANN LA ROCHE (CH) | 2006-10-04 | — | — | CN | disclosed |
| CN-1642911-A | Phthalimido derivatives as inhibitors of monoamine oxidase B | HOFFMANN LA ROCHE (CH) | 2005-07-20 | — | — | CN | disclosed |
| US-6903095-B2 | Nitrogen compounds such as 2-(5-(4-Fluoro-benzyloxy)-1,3-dioxo -1,3-dihydro-isoindol-2-yl)-acetamide, used for prophylaxis of Alzheimer's disease; amine oxidase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2005-06-07 | — | — | US | disclosed |
| US-20040229871-A1 | Phthalimido derivatives and a process for their preparation | CESURA ANDREA (CH) | 2004-11-18 | — | — | US | disclosed |
| US-6660736-B2 | MAO-B inhibitors | HOFFMANN-LA ROCHE INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030195208-A1 | PHTHALIMIDO DERIVATIVES AND A PROCESS FOR THEIR PREPARATION | HOFFMANN-LA ROCHE INC. | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195208-A1 | PHTHALIMIDO DERIVATIVES AND A PROCESS FOR THEIR PREPARATION | MAOB, MAOA, CYP4B1 | POLB 568/4885L3MBTL1 2932/4885ALDH1A1 225/4885 |
| US-20040229871-A1 | Phthalimido derivatives and a process for their preparation | MAOB, MAOA, CYP4B1 | POLB 568/4885L3MBTL1 2932/4885ALDH1A1 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.